Aernoud Fiolet

88 Chapter 3 34. Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99(6):805-807. 35. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. 36. O’Keefe JH, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992;19(7):1597-1600. 37. Deftereos S, Giannopoulos G, Angelidis C, et al. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015;132(15):1395-1403. doi:10.1161/ CIRCULATIONAHA.115.017611 38. Muller DWM, Ellis SG, Topol EJ. Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 1991;17(6):126-131. 39. ClinicalTrials.gov. Colchicine Cardiovascular Outcomes Trial (COLCOT). NCT02551094. https:// clinicaltrials.gov/ct2/show/NCT02551094. Published 2015. Accessed October 17, 2017. 40. ClinicalTrials.gov. Imazio COACS Colchicine for Acute Coronary Syndromes. NCT01906749. https://clinicaltrials.gov/ct2/show/NCT01906749. Published 2013. Accessed October 17, 2017. 41. ANZCTR. The LoDoCo2 Trial: Low Dose Colchicine for secondary prevention of cardiovascular disease. ACTRN12614000093684. https://www.anzctr.org.au/Trial/Registration/TrialReview. aspx?id=363771. Published 2014. Accessed September 30, 2017. 42. ClinicalTrials.gov. Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry (CLEAR-SYNERGY) NCT03048825. https://clinicaltrials.gov/ct2/show/NCT03048825. Published 2017. Accessed October 17, 2017. 43. ClinicalTrials.gov. Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE). NCT02898610. https://clinicaltrials.gov/ct2/show/NCT02898610. Published 2016. Accessed October 17, 2017. 44. Hemkens LG, GloyVL, Olu KK, NordmannAJ, Briel M. Colchicine for prevention of cardiovascular events. Cochrane Libr. 2014. 45. Verma S, Eikelboom JW, Nidorf SM, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015;15(1):1. 46. Niel E, Scherrmann J-M. Colchicine today. Jt Bone Spine. 2006;73(6):672-678. 47. Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med. 1974;291(18):932-934. 48. Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long‐term colchicine treatment in children with familial mediterranean fever. Arthritis Rheum. 1991;34(8):973-977. 49. Banach M, Rizzo M, Toth PP, et al. Statin intolerance–an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci AMS. 2015;11(1):1. 50. Tournoij E, Peters RJG, Langenberg M, Kanhai KJK, Moll FL. The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. Eur J Vasc Endovasc Surg. 2009;37(5):597-603. 51. Hull K. FDAMedical Review. Colchicine for the Treatment of FMF.; 2008. http://www.accessdata . fda.gov/drugsatfda_docs/nda/2009/022352s000_MedR.pdf. 52. Wilbur K, MakowskyM. Colchicine myotoxicity: case reports and literature review. Pharmacother J Hum Pharmacol Drug Ther. 2004;24(12):1784-1792.